We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions regarding Oxford Biomedica Plc (OXB) during the week of January 8 to January 15, 2025, reflected a prevailing sense of anxiety and skepticism about the company's future performance and management's responsiveness to shareholders. The conversation was highlighted by significant trading activity, with one user noting that approximately 440,000 shares were traded, far exceeding the usual volume, although much of it was comprised of smaller trades. Comments such as "Shares lower than they were five years ago. Short it and laugh" by Ken Chung, along with disgruntled remarks about management's communication strategies, pointed towards a lack of confidence among smaller shareholders. Some discussions also included observations on the broader healthcare market sentiment, mentioning disappointing performances from major players like Moderna.
Amidst the dissatisfaction, there were mixed perspectives on potential future collaborations and developments. Notably, Harry S Truman commented on the importance of partnerships, such as with Cabaletta Bio, suggesting that positive outcomes from these alliances could be pivotal for OXB. However, sentiments were generally negative, with phrases like "this piece of shit is going tits up make no mistake about it" echoing through the discussions, highlighting deep-rooted frustrations about the company's handling of shareholder relations. As discussions framed the lack of updates from the company as a driving factor for a decline in investor sentiment, participants expressed a desire for clearer communication moving forward, with some speculating at the necessity of an upcoming trading update amid otherwise quiet management engagement.
Show more
During the past week, Oxford Biomedica PLC (OXB) released significant updates regarding its employee share option scheme and total voting rights. As part of the 2015 Employee Share Option Scheme, 11,197 securities were issued, leaving a total of 283,522 unallotted securities as of the end of December 2024. Additionally, OXB confirmed its total outstanding share capital at 105,961,906 ordinary shares, which reflects stability in its capital structure, necessary for shareholders to determine their interest under the FCA's regulations.
Furthermore, OXB announced board changes with the appointment of Colin Bond as a Non-Executive Director effective January 1, 2025. Bond brings extensive experience from his previous roles, including serving as CFO for notable companies such as Sandoz and Vifor Pharma, positioning him well to contribute to OXB’s strategic initiatives. The company also emphasized its commitment to innovation by hosting a free webinar to showcase advancements in automated manufacturing for viral vector drug products, demonstrating its leadership in the cell and gene therapy sector.
Show more
M&G have held the position in OXB for many years, at varying levels. |
My mistake there - days and years - confusing people since... |
They bought the entire position between June 23 and June 24 according to the accounts so they may have made a decent turn and decided to move on. Perhaps their best performer in the fund looking at some of the other holdings - said in jest of course.... |
Hopefully they were placed with one party at a discount to the recent dip, and a further announcement by that party of an increased holding will give us all a bit of a boost............bef |
M&G holds OXB at 2% in M&G recovery fund....is that where it is being sold down from? |
M&G were at 7% in the annual report. That was before the last tranche of the IM shares were issued, so the effective holding would be closer to 6.7%. So the sell down has been less severe than the holdings announcement implies. |
Seeing as that represents over 5 million shares (a little over half their holding), the sale has either been worked over a significant period of time or else, if a large block sale, we should soon expect to see an announcement of the counter-party who bought them. |
#9568. .... And so it does! |
M&G the British Sports car manufacturer selling. |
You wonder if it’s been a tree shake before news? |
I don't know Dom, but today ADVFN popup ads for me have been for Castle Air private VIP helicopter charters. I'm taking it as a sign. |
Looking like we'll close back over £4. What on earth is going on? |
Appreciate that, thank you. So basically the advice would always be to ring up in person to get the best price for a sizable quantity or I suppose simply set a limit trade and hope for the best. I'd always assumed that the partial order book which we can see on OXB's website is the limit trades sat there waiting to either be taken or expire, but had no way to know that for sure. |
Below is a commentary on NMS .I would guess that normal market size for OXB is perhaps as low as a thousand shares.This means that invariably,a marketmaker will find himself working an order.In the past,a market maker would offer to do an initial trade which was bigger than NMS to kick off the order presuming he was given the balance of the order to work on.Such niceties may of long gone but its not in the interests of a reasonable size holder to go dumping stock in a disorganised fashion and compromise his portfolio valuation.In a thin market like OXB, MMs will be keen to keep a low profile.Its difficult to know what they're up to.Most believe that when an MM pushes up the bid price,he's working a buy order but its quite feasible that he's carrying stock and is trying to offload it by encouraging buyers on the blue. "if you call your broker and ask them to deal in the stock, you can be guaranteed a minimum fill in a certain size and price at least. But if you request a quoted price to buy or sell online then the market makers are not obliged to honour any price or size of transactions. This means that no minimum price or size can be guaranteed when you request a market maker quote through your online broker." |
As stressed many times before, my knowledge of market workings is limited on a good day, but if you look at our chart above and then compare it to the trade list, that crashing dip and then immediate bounce back seems to be about one single £23k trade just before it. |
Anyone who can see the share register (not me) will work out pretty quickly if one of our large holders is having to sell some. As one of our angels of doom turned up yesterday to gloat about it, I'm guessing that is probably the most likely explanation.Alternat |
The share price took a real pounding yesterday but there always seems to be a late buy to get attempt to get the share price back to evens. What is this manipulation? |
Private punters are indeed well down the listOXB don't need them in rights issues or placingsThe share price will come into focus before incentive options are due to expire Those dates may be instructive in the planned schedule of co development |
I'm looking at the 440k traded today (I only saw one big trade in all of that which was 123k before lunch) so a lot of smaller trades made up a day with 4x our usual volume? |
The mood surrounding healthcare is fairly nervous currently.Moderna disappointed yesterday but even a very solid update today by Eli Lily was poorly received with the stock currently down 7 percent.Trump is fairly scathing about pharmaceutical companies believing them to be guilty of profiteering at consumers expense.In this environment,it would be reassuring if OXB was to provide an update but in my experience,healthcar |
Great to get such an intelligent observation? |
Shares lower than they were five years ago.Short it and laugh.Lemmings and mushrooms only. |
Sean, |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 404.50 |
Offer Price | 407.50 |
Open | 400.50 |
Shares Traded | 98,207 |
Last Trade | 16:35:17 |
Low - High | 400.50 - 411.00 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.32 |
Market Cap | 428.29M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads